COHANCE · NSE
Cohance Lifesciences Limited
₹438
-0.44% (-₹1.95)
Prev. close
₹439.95
Volume
6,99,254
Delivery %
51.2%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Cohance Lifesciences Limited
Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluorescent dyes; pellets and finished dosage forms (FDE); packaging and clinical trial support services; and specialty chemicals, including agrochemicals. It serves pharmaceutical, biotechnology, and chemical companies. The company was formerly known as Suven Pharmaceuticals Limited and changed its name to Cohance Lifesciences Limited in May 2025. The company was founded in 1989 and is headquartered in Hyderabad, India. Cohance Lifesciences Limited is a subsidiary of Berhyanda Limited.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Headquarters
Hyderabad
Website
cohance.comExchange
View on NSE ↗Key stats
Market cap
₹16,757.76 Cr
P/E ratio (TTM)
158.1
EPS (TTM)
₹2.77
Beta (1Y · daily vs NIFTY 50)
0.88
Beta (5Y · monthly vs NIFTY 50)
1.20
Shares float
13.81 Cr
EPS · quarter ended Jun 2026
₹-0.65
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (consolidated), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.7% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,009.72 Cr | ₹1,320.22 Cr | ₹1,340.33 Cr | ₹1,034.06 Cr | ₹2,526.22 Cr | ₹2,268.55 Cr | |
| EBITDA | ₹454.72 Cr | ₹671.81 Cr | ₹620.53 Cr | ₹467.22 Cr | ₹847.42 Cr | ₹431.61 Cr |
| ₹362.00 Cr | ₹453.80 Cr | ₹411.29 Cr | ₹300.28 Cr | ₹487.34 Cr | ₹179.23 Cr | |
| Diluted EPS | ₹14.23 | ₹17.83 | ₹16.16 | ₹11.8 | ₹12.68 | ₹4.68 |
Total expenses (as filed), Employee benefit expense, Other expenses, Other income have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,474.00 Cr | ₹1,830.00 Cr | ₹1,966.00 Cr | ₹2,254.00 Cr | ₹5,480.00 Cr | ₹5,727.00 Cr | |
| ₹143.04 Cr | ₹97.13 Cr | ₹70.34 Cr | ₹65.01 Cr | ₹485.93 Cr | ₹400.49 Cr | |
| Stockholders' equity | ₹1,180.00 Cr | ₹1,527.00 Cr | ₹1,735.00 Cr | ₹2,050.00 Cr | ₹3,648.00 Cr | ₹3,911.00 Cr |
CWIP, Others have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹383.00 Cr | ₹330.00 Cr | ₹457.00 Cr | ₹358.00 Cr | ₹673.00 Cr | ₹368.00 Cr | |
| Investing cash flow | ₹-311.40 Cr | ₹-136.14 Cr | ₹-194.84 Cr | ₹-362.35 Cr | ₹-389.70 Cr | ₹-254.57 Cr |
| ₹-76.00 Cr | ₹-156.00 Cr | ₹-242.00 Cr | ₹-14.00 Cr | ₹-327.00 Cr | ₹-165.00 Cr | |
| Capital expenditure | ₹-111.00 Cr | ₹-75.00 Cr | ₹-286.00 Cr | ₹-52.00 Cr | ₹-317.00 Cr | ₹-220.00 Cr |
| End cash position | ₹7.18 Cr | ₹44.56 Cr | ₹64.80 Cr | ₹47.23 Cr | ₹96.65 Cr | ₹49.14 Cr |
Debt issued, Debt repaid, Dividends paid have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Dec 23(10Q) | Mar 24–Mar 25(5Q) | May 25–Jun 25(2Q) | Sep 25–Jun 26(4Q) |
|---|---|---|---|---|
| Promoter | 60.00% | 50.10% | 66.41% | 57.49% |
| Public | 40.00% | 49.90% | 33.59% | 42.51% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Cohance Lifesciences Limited | ₹16,832.37 Cr | ₹438 | 158.8 | 4.30 | 4.6% | 0.10 | -12.8% | -52.0% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
25 indices
NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.